Blueprint Medicines Corp’s recently made public that its CHIEF EXECUTIVE OFFICER Haviland Kate unloaded Company’s shares for reported $0.22 million on Apr 01 ’25. In the deal valued at $86.65 per share,2,498 shares were sold. As a result of this transaction, Haviland Kate now holds 165,929 shares worth roughly $13.55 million.
Then, KATHRYN D HAVILAND bought 2,498 shares, generating $221,098 in total proceeds.
Before that, Rossi Christina sold 2,274 shares. Blueprint Medicines Corp shares valued at $216,075 were divested by the CHIEF OPERATING OFFICER at a price of $95.02 per share. As a result of the transaction, Rossi Christina now holds 69,266 shares, worth roughly $5.66 million.
A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid March with a ‘”an Outperform”‘ rating. Jefferies began covering BPMC with “Buy” recommendation on March 17, 2025. Scotiabank started covering the stock on March 07, 2025. It rated BPMC as “a Sector outperform”.
Price Performance Review of BPMC
On Friday, Blueprint Medicines Corp [NASDAQ:BPMC] saw its stock fall -6.23% to $81.68. Over the last five days, the stock has lost -7.94%. Blueprint Medicines Corp shares have fallen nearly -6.35% since the year began. Nevertheless, the stocks have fallen -11.44% over the past one year. While a 52-week high of $121.90 was reached on 01/27/25, a 52-week low of $80.68 was recorded on 04/04/25. SMA at 50 days reached $95.94, while 200 days put it at $96.33.
Levels Of Support And Resistance For BPMC Stock
The 24-hour chart illustrates a support level at 79.17, which if violated will result in even more drops to 76.67. On the upside, there is a resistance level at 85.09. A further resistance level may holdings at 88.51. The Relative Strength Index (RSI) on the 14-day chart is 35.68, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.88, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 89.96%. Stochastics %K at 26.65% indicates the stock is a holding.
How much short interest is there in Blueprint Medicines Corp?
A steep rise in short interest was recorded in Blueprint Medicines Corp stocks on 2025-03-14, growing by 0.12 million shares to a total of 5.02 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 4.9 million shares. There was a rise of 2.39%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 14, 2024 when JP Morgan began covering the stock and recommended ‘”an Overweight”‘ rating along with a $126 price target.
